Stay updated with breaking news from Nasdaq Fold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) from a hold rating to a buy rating in a research note published on Monday. FOLD has been the subject of several other reports. UBS Group raised their target price on Amicus Therapeutics from $15.00 to $17.00 and gave the stock a buy rating in […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) – Stock analysts at SVB Leerink lowered their Q1 2023 earnings per share estimates for shares of Amicus Therapeutics in a report issued on Wednesday, March 1st. SVB Leerink analyst J. Schwartz now expects that the biopharmaceutical company will earn ($0.07) per share for the quarter, down from […]
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term...
Nisa Investment Advisors LLC trimmed its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 13.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 7,440 shares of the biopharmaceutical company’s stock after selling 1,140 shares during the period. Nisa Investment Advisors LLC’s holdings in […]
SG Americas Securities LLC lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 63.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,218 shares of the biopharmaceutical company’s stock after selling 92,568 shares during […]